Pioneering the Future of Kidney Care
Medtech Renal is developing a non-invasive, wearable alternative to dialysis, restoring renal function in 45 minutes a day from home.
Medtech Renal
Medtech Renal is a seed-stage start-up company pioneering an innovative, low-risk medical device designed to offer an alternative to dialysis. The company is developing a wearable non-invasive medical device to be used in the home for just 45 minutes per day to improve renal function in persons suffering from chronic renal failure.
The Problem
Today's gold standard is failing the patients who need it most.
When kidneys fail, the only treatment options available are either transplant or dialysis, with dialysis being the most common.
The Quality of Life Gap
There are currently 15,000 Australians on dialysis. Remarkably, the AIHW estimates 50% of new cases of renal failure each year (3,300 Australians) will choose end-of-life care over dialysis.
The Global Access Gap
Globally, over 3 million people are on dialysis. An estimated 7–9 million people need treatment but cannot access it due to lack of affordability.
The Historical Trend
Over the last 20 years, renal disease has risen from the 19th leading cause of death (Year 2000) to the 9th leading cause of death worldwide (WHO, 2020).
The Future Projection
By 2040, renal disease is estimated to be the 5th leading cause of death globally (Kovesdy, 2022).
Our solution
Restoring function through non-invasive Nitric Oxide stimulation
Medtech Renal is pioneering a low-risk, wearable alternative to dialysis, designed to improve the quality of life for those suffering from chronic renal failure.
- Non-Invasive Wearable: A low-risk, needle-free alternative to traditional, invasive dialysis treatments.
- Nitric Oxide Stimulation: Restores critical $NO$ levels to naturally improve and support renal filtration.
- 45-Minute Daily Therapy: High-efficiency treatment designed to fit into a single 45-minute window each day.
- At-Home Freedom: Eliminates exhausting clinic visits by allowing patients to treat themselves from home.
- Global Accessibility: An affordable, scalable solution for the 7–9 million people currently priced out of care.
Supported by
Flinders University, Industry Growth Program, QUT Bridgetech Program, Medtech Actuator, Australasian Kidney Trials Network.
